Newsroom | 4633 results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 35,900 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as in...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our long-term goal of developing and ultimately commercializing new innovative medicines for millions of patients. We...

NEW YORK--(BUSINESS WIRE)--Unite Us, the nation’s trusted technology partner for integrating health and community-based care, reports significant health improvements from a year-long collaboration with Jordan Health and Foodlink through the Finger Lakes Performing Provider System’s (FLPPS) System Transformation & Community Investment program. Together, they launched the Healthy Eating Pilot Program, a local initiative in the Finger Lakes region focused on addressing food insecurity among pa...

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today an advancement in the use of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide. By applying AI to electronic health record (EHR) deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights—such as side effects, dis...

WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical announces financial and operational results for the three months ended March 31, 2025....

BOSTON--(BUSINESS WIRE)--A new data tool from Pioneer Institute reveals that federal drug price controls—intended to reduce out-of-pocket costs for seniors—are instead making many prescription drugs more expensive for Medicare beneficiaries. The IRA Medicare Drug Access Tracker, developed by Dr. William Smith and Dr. Robert Popovian, monitors the impact of the Inflation Reduction Act’s (IRA) drug pricing provisions. Its first analysis shows that among nine commonly prescribed medications which...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. “Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a...

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc announces that it has been selected as winner of the “Best Overall Digital Health Company” award by MedTech Breakthrough....

BOSTON--(BUSINESS WIRE)--OM1: What: OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1’s Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI). Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation. W...

澳大利亚悉尼--(BUSINESS WIRE)--(美国商业资讯)-- 国际卓越的临床研究组织 (CRO) 和科学咨询公司Novotech（诺为泰）发布了一份报告，深度剖析了肥胖症临床试验趋势。报告显示，2019年至2024年间，全球肥胖症临床试验数量增加了两倍，研究活动显著增加，治疗选择不断丰富，前景可期。 肥胖症仍是全球重大健康挑战，全球逾9亿成年人罹患肥胖症，对医疗体系及生活质量构成沉重负担。作为2型糖尿病、心血管疾病、肌肉骨骼疾病及部分癌症的重要诱因，肥胖症亟需靶向创新治疗策略。 本报告全面分析了肥胖症治疗领域的新兴疗法、生物标志物研究进展与全球投资趋势，为生物技术和制药企业提供有力行业参考。鉴于各地区肥胖症发病率持续上升，本报告提供了可行的市场洞察与战略分析，助力企业推进肥胖症治疗管线，科学规划产品开发与商业化路径。 诺为泰在临床领域与监管事务方面具有丰富的经验，与全球5000多个试验点建立了合作关系，致力于加速临床开发进程。凭借全面的本地市场洞察力和先进的分析能力，助力生物技术和制药创新企业高效开展复杂试验。 点击此处下载《全球临床试验概况》完整版报告。 如需更多信息，请访...